Jan 8, 2026 08:03AM
Jan 8, 2026 08:00AM
Jan 5, 2026 04:35AM
Dec 24, 2025 06:44AM
Dec 23, 2025 08:03AM
Dec 23, 2025 08:00AM
Nov 13, 2025 04:05PM Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Nov 10, 2025 08:00AM
Oct 27, 2025 06:50AM
Sep 15, 2025 09:04AM
Aug 14, 2025 04:25PM
Jun 2, 2025 07:02AM
Jun 2, 2025 07:00AM
May 15, 2025 04:05PM Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights
Dec 20, 2024 07:01AM
Dec 20, 2024 07:00AM
Dec 16, 2024 08:05AM
Dec 16, 2024 08:00AM
Nov 14, 2024 05:25PM
Nov 12, 2024 08:06AM
Nov 12, 2024 08:00AM Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
Sep 9, 2024 08:04AM
Sep 9, 2024 08:00AM
Aug 27, 2024 08:00AM
Aug 14, 2024 08:00AM
Aug 6, 2024 08:02AM
Aug 6, 2024 08:00AM
Jul 11, 2024 10:33AM H.C. Wainwright Reiterates Buy Rating on Reviva Pharmaceuticals (RVPH)
Jul 9, 2024 08:12AM
Jul 9, 2024 08:00AM
May 29, 2024 04:45PM
May 28, 2024 08:01AM
May 28, 2024 08:00AM
May 15, 2024 08:00AM
May 14, 2024 08:00AM Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 13, 2024 08:00AM
May 9, 2024 08:00AM
Apr 15, 2024 08:31AM
Apr 15, 2024 08:30AM
Apr 15, 2024 08:05AM
Mar 28, 2024 08:00AM
Mar 26, 2024 08:00AM Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting
Feb 6, 2024 08:00AM
Jan 4, 2024 08:00AM
Dec 11, 2023 08:35AM
Dec 11, 2023 08:00AM
Nov 30, 2023 04:05PM
Nov 20, 2023 04:05PM
Nov 16, 2023 08:00AM Reviva Pharmaceuticals (RVPH) Announces $30 Million Registered Direct Offering of Common Stock, Warrants
Nov 16, 2023 08:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All